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Asymptomatic HCM
Exercise Capacity, and Not LV Outﬂow Tract Gradient Predicts
Long-Term Outcomes
Milind Y. Desai, MD, Aditya Bhonsale, MD, Parag Patel, MD, Peyman Naji, MD,
Nicholas G. Smedira, MD, Maran Thamilarasan, MD, Bruce W. Lytle, MD,
Harry M. Lever, MD
Cleveland, OhioOBJECTIVES This study sought to assess long-term outcomes in asymptomatic or minimally symp-
tomatic patients with hypertrophic cardiomyopathy (HCM) who underwent exercise echocardiography,
without invasive therapies for relief of left ventricular outﬂow tract (LVOT) obstruction.
BACKGROUND Many HCM patients present with LVOT obstruction, mitral regurgitation (MR), and
diastolic dysfunction, often requiring invasive therapies for symptomatic relief. However, a signiﬁcant
proportion of truly asymptomatic patients can be closely monitored. In HCM patients, exercise echocar-
diography has been shown to be a useful assessment of functional capacity and risk stratiﬁcation.
METHODS We included 426 HCM patients (44  14 years; 78% men) undergoing exercise echocardi-
ography, excluding hypertensive heart disease of elderly, ejection fraction <50% and invasive therapy
(myectomy or alcohol ablation) during follow-up. Clinical, echocardiographic (LV thickness, LVOT gradient,
and MR) and exercise variables (percent of age-sex predicted metabolic equivalents [METs] and heart rate
recovery [HRR] at 1 min post-exercise) were recorded. A composite endpoint of death, appropriate inter-
nal deﬁbrillator discharge, and admission for congestive heart failure was recorded.
RESULTS Patients were asymptomatic or minimally symptomatic on history, but 82% of patients
achieved <100% of age-sex predicted METs, and 43% had $IIþ post-stress MR. The mean LV septal
thickness, post-exercise LVOT gradient, and HRR were 2.0  0.5 cm, 62  47 mm Hg, and 31  14
beats/min, respectively. During a mean follow-up of 8.7  3 years, there were 52 events (12%). Patients
achieving >100% of age-sex predicted METs had 1% event rate versus 12% in those achieving <85%.
On stepwise multivariate survival analysis, percent of age-sex predicted METs (hazard ratio [HR]: 0.76;
95% conﬁdence interval [CI]: 0.64 to 0.90), abnormal HRR (HR: 0.89; 95% CI: 0.82 to 0.97), and atrial ﬁbril-
lation (HR: 2.73; 95% CI: 1.30 to 5.74) (overall, p < 0.001) independently predicted outcomes.
CONCLUSIONS In asymptomatic or minimally symptomatic HCM patients, exercise stress testing
provides excellent risk stratiﬁcation, with a low event rate in patients achieving >100% of predicted
METs. (J Am Coll Cardiol Img 2014;7:26–36) ª 2014 by the American College of Cardiology FoundationFrom the Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. All authors have reported that they have no
relationships relevant to the contents of this paper to disclose.
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27ypertrophic cardiomyopathy (HCM) is a echocardiography. No patient was a competitive
heterogeneous inherited cardiomyopathy
with variable phenotypic expression that
ranges from asymptomatic status to heart
failure to sudden death, which occurs in <1%/year
(1–3). Disease progression is often due to diastolic
dysfunction, mitral regurgitation (MR), and left
ventricular outﬂow tract (LVOT) obstruction (4).
All the above processes result in reduction of exer-
cise capacity and could ultimately progress to
congestive heart failure (CHF) and death. InSee page 37
A B B R E V I A T I O N S
A N D A C R O N YM S
AF = atrial ﬁbrillation
CHF = congestive heart failure
HCM = hypertrophic
cardiomyopathy
HR = hazard ratio
HRR = heart rate recovery
ICD = implantable cardioverter-
deﬁbrillator
LVOT = left ventricular
outﬂow tract
METs = metabolic equivalents
MR = mitral regurgitation
VT = ventricular tachycardiaintractably symptomatic HCM patients, invasive
therapies to relieve LVOT obstruction (surgical
myectomy with or without mitral valve surgery or
alcohol septal ablation) are associated with excellent
long-term outcomes (5–12). These therapies, when
offered to symptomatic patients, result in long-term
survival similar to that of a healthy population
(5,10).
Often, patients’ perceptions about their symp-
toms can be misleading. In many situations, the
symptoms are equivocal. In these instances, exercise
testing can further aid in risk stratiﬁcation for future
events, as previously described in many populations
(13–15). In general, patients with reduced exercise
capacity have a worse prognosis as compared to those
who have preserved capacity. Indeed, studies have
demonstrated that exercise capacity, along with heart
rate recovery (HRR), following exercise are predictive
of long-term outcomes in various patient populations
(13–16). In HCM, exercise echocardiography is
deemed safe and is commonly used to assess: 1) pa-
tients with equivocal symptoms; 2) functional capacity
prior to a corrective therapeutic procedure; and 3) risk
stratiﬁcation (3). We sought to assess the prognostic
utility of various treadmill echocardiographic variables
on long-term outcomes in a consecutive group of
asymptomatic or minimally symptomatic HCM pa-
tients referred for clinical assessment and
risk stratiﬁcation and who did not undergo invasive
therapies for relief of LVOT obstruction.METHODS
Study population. The study population was a
part of an institutional review board–approved
observational registry of HCM patients, with the
initial visit between January 1997 and December
2007. In the current study, we included only HCM
patients who were able to undergo treadmillathlete. The diagnosis of HCM was made by cardi-
ologists experienced in this disease, on the basis of
typical clinical, electrocardiographic, and echocar-
diographic features, with ventricular myocardial hy-
pertrophy (LV wall thickness$15 mm) occurring in
the absence of any other cardiac or systemic disease
that could have been responsible for the hypertrophy
(3). Additionally, in patients with borderline LV wall
thickness (w15 mm), the presence of resting or
provocable LVOT obstruction (LVOT gradient
$30 mm Hg) also aided in the diagnosis (3).
We excluded the following patients: 1) those age
<18 years; 2) those with hypertensive heart disease
of the elderly with concomitant LVOT obstruction
(17–19); 3) those with ejection fraction <50%; 4)
those with more than mild aortic or mitral stenosis
on initial echocardiography; and 5) patients who
underwent invasive therapies to relieve LVOT
obstruction (surgical myectomy with or
without mitral valve surgery or alcohol
ablation) during follow-up. Hypertensive
heart disease of the elderly with concomi-
tant LVOT obstruction was deﬁned as a
long-standing history of hypertension and
characteristic sigmoid-shaped basal septal
hypertrophy, identiﬁed on echocardiogra-
phy (17–20). These patients were excluded,
after clinical/imaging evaluation, because
they have different pathophysiologic and
genetic proﬁles (20). The ﬁnal study pop-
ulation consisted of 426 patients.
Demographic, clinical, medication, and
electrocardiographic data obtained at the
time of initial and follow-up visits were
recorded from electronic medical records. The pres-
ence of atrial ﬁbrillation (AF) was recorded according
to guidelines (21). Nonsustained ventricular tachy-
cardia (VT), wide complex tachycardia at 120 beats/
min or higher lasting>3 beats but<30 s, or sustained
VT lasting>30 s, was recorded on the basis of history
and Holter monitor data. The presence of an
implantable cardioverter-deﬁbrillator (ICD) and/or
permanent pacemaker was ascertained.
Resting echocardiography. All patients underwent
comprehensive echocardiography using commer-
cially available instruments (HDI 5000, Philips
Medical Systems, N.A., Bothell, Washington; and
Acuson Sequoia, Siemens Medical Solutions Inc.,
Malvern, Pennsylvania). Maximal end-diastolic LV
wall thickness, LV dimensions, and left atrial area
were measured according to guidelines (22).
Resting LVOT peak velocity was measured by
continuous-wave Doppler echocardiography, and
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28resting LVOT pressure gradient was estimated by
using simpliﬁed Bernoulli equation. Care was taken
to avoid contamination of the LVOT waveform by
MR. In patients with resting LVOT gradients
<30 mm Hg, provocative maneuvers, including
Valsalva and amyl nitrite, were used to provoke
LVOT gradient. The degree of resting MR was
assessed (0 ¼ none; 1þ ¼ mild; 2þ ¼ moderate;
3þ ¼ moderately severe; and 4þ ¼ severe) using
multiple criteria (23). Grades of resting diastolic
function were assigned in each individual on the
basis of multiple criteria (E-to-A ratio, deceleration
time, left atrial area, LV ejection fraction) (24).
Tissue Doppler data were not uniformly available
and hence not utilized.
Stress echocardiography. In conjunction with
echocardiography, patients underwent a symptom-Table 1. Baseline Characteristics of the Study Population
All Patients
(N [ 426)
Asymmetr
Hypert
Without O
(n [
Age, yrs 44  14 43 
Male 310 (73) 84 (
BSA, m2 2.01  0.3 1.99 
Disease history
HTN 125 (32) 31 (
Syncope 69 (16) 21 (
AF 65 (15) 29 (
CAD 27 (6) 4 (
DM 21 (5) 2 (
Stroke 9 (2) 4 (
SCD 7 (1.6) 2 (
Family history of HCM 105 (25) 46 (
Treatment history
Devices
ICD 33 (8) 14 (
Pacemaker 30 (7) 9 (
Medications
Beta-blocker 253 (60) 60 (
CCB 87 (20) 18 (
Disopyramide 12 (3) 2 (
Medical treatment after initial visit 387 (91) 93 (
NYHA functional class*
I 283 (66) 74 (
II 143 (34) 42 (
Values are mean  SD or n (%). *Because excluded patients who subsequently need
class III or IV disease.
AF ¼ atrial ﬁbrillation; BSA ¼ body surface area; CAD ¼ coronary artery disease;
cardiomyopathy; HTN ¼ hypertension; ICD ¼ implantable cardioverter-deﬁbrillator;limited exercise treadmill test using either Bruce
(standard or modiﬁed) or Cornell protocol, as
previously described (25). Patients took their
medications on the day of the test. BP, heart rate,
and electrocardiographic measurements were made
at rest, at 1-min intervals, and for at least 6 min in
recovery. Resting and peak exercise rate-pressure
product (systolic BP  heart rate), maximal pre-
dicted heart rate (220 – age), percent of predicted
maximal heart rate, HRR (drop in heart rate from
peak to 1 min post-exercise [16]), and number of
metabolic equivalents (METs) (achieved as well as
what would be expected on the basis of age and
sex) were recorded. For men, we used the Veterans
Affairs cohort formula (predicted METs ¼ 18
– [0.15  age]) (26), and for women we used the
St. James Take Heart Project formula (predictedic Septal
rophy
bstruction
116)
Asymmetric Septal
Hypertrophy
With Obstruction
(n [ 280)
Apical
Hypertrophy
(n [ 30) p Value
14 45  14 45  15 0.4
72) 200 (71) 26 (87) 0.2
0.3 2.01  0.3 2.04  0.3 0.7
27) 83 (30) 11 (37) 0.6
18) 44 (16) 4 (13) 0.7
25) 32 (11) 4 (15) 0.003
3) 21 (8) 2 (7) 0.3
2) 16 (6) 3 (10) 0.1
3) 5 (2) 0 (0) 0.4
1.7) 4 (1.4) 1 (3.3) 0.7
40) 51 (18) 8 (27) 0.001
12) 17 (6) 2 (7) 0.1
8) 19 (7) 2 (7) 0.7
52) 178 (63) 15 (50) 0.2
16) 65 (23) 4 (13) 0.4
2) 10 (3) 0 (0) 0.7
80) 267 (95) 27 (90) 0.002
0.2
64) 185 (66) 24 (80)
36) 95 (34) 6 (20)
ed invasive therapies were excluded, none of the patients had NYHA functional
CCB ¼ calcium channel blocker; DM ¼ diabetes mellitus; HCM ¼ hypertrophic
NYHA ¼ New York Heart Association; SCD ¼ sudden cardiac death.
Table 2. Resting and Exercise Echocardiographic Parameters of the Study Population
All Patients
(N [ 426)
Asymmetric Septal
Hypertrophy Without
Obstruction
(n [ 116)
Asymmetric Septal
Hypertrophy With
Obstruction
(n [ 280)
Apical
Hypertrophy
(n [ 30) p Value
Resting echocardiography
LVEF, % 61  5 61  5 61  5 62  5 0.3
Maximal LV thickness, cm 2.0  0.5 2.1  0.5 2.0  0.5 1.6  0.6 <0.001
Left atrial dimensions, cm 4.2  0.8 4.2  0.8 4.2  0.7 4.1  0.7 0.4
Resting MR 0.02
None 45 (11) 19 (16) 22 (8) 4 (13)
1þ 332 (78) 91 (78) 216 (77) 25 (83)
IIþ 40 (9) 6 (5) 33 (12) 1 (3)
IIIþ 9 (2) 0 (0) 9 (3) 0 (0)
Diastolic function 0.06
Impaired relaxation 399 (93) 106 (91) 266 (95) 27 (90)
Pseudonormal 24 (6) 7 (6) 14 (5) 3 (10)
Restrictive ﬁlling 3 (1) 3 (3) 0 (0) 0 (0)
Resting LVOT gradient, mm Hg <0.001
Mean  SD 28  32 7  4 32  29 15  18
Median (IQR) 12 (8–35) 7 (5–9) 18 (10–54) 9 (6–44)
Resting SAM of mitral valve 105 (25) 0 (0) 105 (38) 0 (0) < 0.001
Treadmill exercise echocardiography
Post-stress LVOT gradient, mm Hg <0.001
Mean  SD 62  47 12  9 86  39 26  38
Median (IQR) 59 (20–93) 12 (6–24) 81 (58–110) 11 (0–36)
Peak-stress SAM of mitral valve 233 (55) 0 (0) 233 (83) 0 (0) <0.001
Peak-stress MR 0.2
None 45 (11) 19 (16) 22 (8) 4 (13)
1þ 197 (46) 52 (45) 131 (47) 14 (47)
IIþ 137 (32) 38 (33) 89 (32) 10 (33)
IIIþ 43 (10) 7 (6) 34 (12) 2 (7)
IVþ 4 (1) 0 (0) 4 (1) 0 (0)
Peak heart rate, beats/min 150  26 149  27 150  25 153  30 0.8
Peak BP, mm Hg
SBP 168  35 162  41 170  33 175  30 0.07
DBP 80  14 79  16 81  14 79  13 0.4
Peak rate-pressure product 26,223  10,372 24,906  7,894 26,063  6,717 32,794  8,943 0.001
Abnormal BP drop at peak exercise 5 (1.2) 1 (0.9) 4 (1.4) 0 (0) 0.7
Peak METs achieved 8.4  2.6 8.4  2.8 8.2  2.4 9.6  3.2 0.02
Age-sex predicted METs 0.09
<85% 268 (63) 76 (63) 177 (66) 15 (50)
85%–100% 82 (19) 22 (19) 56 (20) 4 (13)
>100% 76 (18) 18 (16) 47 (17) 11 (37)
Abnormal chronotropic reserve index 149 (35) 48 (41) 93 (33) 8 (27) 0.2
Heart rate recovery, beats/min 31  14 31  15 31  14 32  11 0.8
Values are mean  SD, n (%), or median (IQR).
BP ¼ blood pressure; DBP ¼ diastolic blood pressure; IQR ¼ interquartile range; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; LVOT ¼ left ventricular
outﬂow tract; METs ¼ metabolic equivalents; MR ¼ mitral regurgitation; SAM ¼ systolic anterior motion; SBP ¼ systolic blood pressure.
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Table 3. Univariate Cox Proportional Hazards Survival Analysis of
Composite Events (N [ 426)
HR (95% CI) p Value
Age (10-year increment) 1.13 (0.85–1.50) 0.4
Sex 1.09 (0.49–2.43) 0.8
BSA 0.73 (0.18–2.88) 0.5
HTN 1.49 (0.74–3.00) 0.2
DM 1.79 (0.09–33.1) 0.6
CAD 1.60 (0.37–6.84) 0.4
Family history of HCM 1.32 (0.62–2.79) 0.4
Syncope 1.23 (0.50–3.04) 0.6
Medical treatment for HCM 1.10 (0.70–1.71) 0.6
NYHA functional class at ﬁrst visit 1.63 (0.84–3.16) 0.13
VT 1.65 (0.67–4.05) 0.2
Pacemaker 1.73 (0.68–4.44) 0.2
AF 2.39 (1.05–5.42) 0.03
Maximal LV thickness 1.40 (0.85–2.32) 0.2
LVEF 0.98 (0.92–1.04) 0.6
Left atrial area 1.38 (0.83–2.32) 0.3
Resting LVOT gradient (10-mm Hg increment) 1.05 (0.91–1.21) 0.5
Post-stress LVOT gradient (10-mm Hg increment) 1.01 (0.93–1.09) 0.9
Diastolic dysfunction 1.51 (0.72–3.02) 0.3
Resting MR 1.57 (0.88–1.75) 0.12
Peak post-stress MR 1.27 (0.87–1.85) 0.2
Apical variant 1.58 (0.80–3.13) 0.2
Abnormal BP response at peak stress 1.96 (0.20–3.27) 0.4
Ventricular arrhythmias during stress test 1.25 (0.51–3.10) 0.6
Peak METs achieved 0.73 (0.63–0.85) 0.001
% Age-sex predicted METs achieved 0.73 (0.62–0.86) 0.001
Abnormal chronotropic reserve index 0.72 (0.41–1.26) 0.7
Abnormal heart rate recovery at 1 min in recovery 0.86 (0.79–0.92) 0.001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; VT ¼ ventricular tachycardia; other abbreviations as in Tables 1
and 2.
Table 4. Stepwise M
Composite Events (N
% Age-sex predicted
Abnormal heart rate r
AF
Deﬁbrillators were not in
endpoints. Overall chi-sq
absolute METs achieved a
Abbreviations as in Tabl
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30METs ¼ 14.7 – [0.13  age]) (27). These for-
mulas have been previously demonstrated to perform
best, in respective sexes, in their ability to predict
outcomes (28). Using that, we calculated theultivariate Cox Proportional Hazards Survival Analysis for
[ 426)
HR (95% CI) p Value
METs achieved* 0.76 (0.64–0.90) 0.001
ecovery at 1 min in recovery 0.89 (0.82–0.97) 0.007
2.73 (1.30–5.74) 0.007
cluded in this analysis because deﬁbrillator discharge was one of the primary
uare: 34; p < 0.001. *Because % of age-gender predicted METs incorporated
long with age and sex, it was used in stepwise multivariate model.
es 1 and 3.following ratio: (METs achieved/predicted
METs)  100. Abnormal HRR was deﬁned as
<12-beat drop over 1 min in recovery (16). We also
calculated chronotropic reserve index as follows (29):
peak heart rate – resting heart rate/220 – age.
Abnormal chronotropic reserve index was deﬁned as
<0.62 if on beta-blockers and <0.8 if not on beta-
blockers. Abnormal BP response, deﬁned as a 20-
mm Hg drop in systolic BP at peak stress, was
recorded (30,31).
Prior to initiating the stress test, resting echo-
cardiographic views were recorded, as per guidelines
(32). In addition to resting wall motion abnormal-
ities, presence/absence of systolic anterior motion of
mitral valve was ascertained, and presence and de-
gree of MR and resting LVOT gradient were
recorded. Immediately following exercise, regional
wall motion abnormalities, MR, and peak exercise
LVOT gradient (and presence of systolic anterior
motion of mitral valve) were recorded. Major events
(sustained ventricular or atrial arrhythmias associated
with severe symptoms, hemodynamic compromise,
or need for cardioversion) and minor events
(decrease in BP, transient symptoms, or non-
sustained arrhythmias) were recorded.
Outcomes assessment. Death notiﬁcation was
conﬁrmed by observation of death certiﬁcate or veri-
ﬁcation with a family member. The duration of
follow-up ranged between the initial stress test to
December 2012. The primary endpoint was a com-
posite of death, appropriate ICD discharges, resusci-
tated sudden death, and admission for CHF. The
cause of death was ascertained as sudden death, death
due to progressive CHF, or “other,” after review of
electronic records and/or discussion with family
members. Sudden death was deﬁned as unexpected
sudden collapse occurring <1 h from the onset of
symptoms in patients who had previously experienced
a relatively stable clinical course (33). In addition, we
recorded successful resuscitation from cardiac arrest or
appropriate ICD shocks (with deﬁbrillation threshold
of >200 beats documented by electrocardiogram re-
views) because they were regarded as equivalents of
sudden death (33). Stroke (transient or permanent
neurological impairment and disability due to vascular
causes, including episodes lasting <24 h) was recor-
ded, along with its cause, either ischemic or embolic.
Statistical analyses. Continuous variables are
expressed as mean  SD and/or median and were
compared using Student t test (for parametric vari-
ables) or Mann-Whitney test (for nonparametric
variables). Categorical data are expressed as percent
frequency and were compared with chi square. Cox
proportional hazards survival models for composite
Figure 1. Outcomes by HCM Phenotype
Kaplan-Meier curves demonstrating long-term outcomes, by hypertrophic cardiomyopathy
(HCM) phenotype.
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31endpoints were then constructed using boot-
strapping (1,000 bootstrapped models were gener-
ated and variables that entered the model at least
75 times were considered signiﬁcant). We utilized
bootstrapping to increase reliable assessment of risk
factors by improving the precision of estimate. In
this manner, univariate hazard ratios (HRs) for
various predictors of composite outcomes were
initially generated individually. Subsequently, a
stepwise multivariate model for composite outcomes
was generated. Data are reported as HRs with 95%
conﬁdence intervals (CIs). Cumulative event rates as
a function over time were obtained by the Kaplan-
Meier method, and different event curves were
compared using the log-rank test. Statistical analysis
was performed using SPSS version 11.5 (SPSS Inc.,
Chicago, Illinois). A p value <0.05 was considered
signiﬁcant.
RESULTS
The baseline data of the study population are
shown in Table 1. These were also divided into 3
subgroups on phenotypic basis: asymmetrical sep-
tal hypertrophy with maximal LVOT obstruction
$30 mm Hg, nonobstructive asymmetrical septal
hypertrophy (<30 mm Hg), and apical hypertrophy
variant. Although approximately one-third had a
history of hypertension, it was not deemed severe
enough to cause the degree of ventricular hyper-
trophy. A signiﬁcantly higher proportion of patients
in the obstructive subgroup were on HCM-related
medical therapy. Because we excluded patients
that subsequently needed invasive therapies, there
were no patients in New York Heart Association
functional class III or IV.
Resting and stress echocardiographic variables, for
the entire study population as well as by phenotype,
are shown in Table 2. There was no peak-stress ev-
idence of ischemia (suggested by a new echocardio-
graphic wall motion abnormality at peak stress).
Because of the use of beta-blockers, only 262 patients
(62%) achieved $85% predicted maximal heart rate
(64 [55%] in the nonobstructive subgroup, 179
[64%] in the obstructive subgroup, and 16 [53%] in
the apical hypertrophy subgroup; p ¼ 0.2). The
number of achieved METs and peak rate-pressure
product were signiﬁcantly higher in the apical
variant. Twenty-ﬁve patients (6%) had an abnormal
HRR (11 [10%] in the nonobstructive subgroup, 13
[5%] in the obstructive subgroup, and 1 [3%] in the
apical hypertrophy subgroup; p ¼ 0.2). Because of
baseline abnormalities, no electrocardiogram was
diagnostic for ischemia. There were no signiﬁcantarrhythmias, syncope, deaths, or ICD discharges
during the stress test. Five patients (2 in the
obstructive subgroup, 2 in the nonobstructive sub-
group, and 1 in the apical subgroup) had a short run of
nonsustained VT that spontaneously resolved.
Follow-up data. During follow-up, 40 patients (9%)
had nonsurgical therapy for management of AF (all
had direct current cardioversions, and 25 had pul-
monary vein isolations). However, 52 patients
(12%) remained in AF during follow-up and were
treated with amiodarone (28 [24%] in the non-
obstructive subgroup, 20 [7%] in the obstructive
subgroup, and 4 [13%] in the apical hypertrophy
subgroup; p ¼ 0.3). Of the entire population, 299
patients (70%) had Holter monitoring performed.
Nonsustained VT and sustained VT (on Holter
monitoring) were noted in 64 (15.0%) and 3 (0.7%)
patients, respectively, with no differences within
subgroups. Also during follow up, there were an
additional 13 patients (3%) with pacemaker im-
plantation, resulting in a total of 43 (10%) patients
(16 [14%] in the nonobstructive subgroup, 24 [9%]
in the obstructive subgroup, and 3 [10%] in the
apical hypertrophy subgroup; p ¼ 0.3). Similarly,
during follow up, there were an additional 74 pa-
tients (17%) with ICD implantation, resulting in a
total of 107 patients (25%) (39 [34%] in the non-
obstructive subgroup, 59 [21%] in the obstructive
subgroup, and 9 [30%] in the apical hypertrophy
subgroup; p < 0.01).
Outcomes and survival data. During a mean follow-
up of 8.7  3.0 years, a total of 52 patients (12%)
Table 5. Clinical and Exercise Echocardiographic Variables, Separated on % Age-Sex
Predicted METs Achieved (N [ 426)
<85%
(n [ 268)
85%–100%
(n [ 82)
>100%
(n [ 76)
p
Value
Age 42  14 45  14 51  11 <0.001
Sex 202 (75) 57 (70) 51 (67) 0.2
BSA 2.04  0.3 1.95  0.2 1.94  0.2 0.008
HTN 69 (26) 25 (31) 31 (41) 0.2
CAD 20 (8) 3 (4) 4 (5) 0.4
History of AF 49 (18) 10 (12) 6 (8) 0.06
Beta-blocker 173 (65) 44 (54) 36 (47) 0.06
CCB 62 (23) 17 (21) 8 (11) 0.2
NYHA functional class <0.001
I 147 (55) 71 (87) 65 (86)
II 121 (45) 11(13) 11 (14)
LVEF, % 62  5 61  5 61  5 0.3
Maximal LV thickness, cm 2.1  0.6 1.9  0.5 1.8  0.4 <0.001
Left atrial dimensions, cm 4.3  0.8 4.0  0.8 4.0  0.1 0.002
Resting MR 0.6
None 24 (9) 9 (11) 12 (16)
1þ 212 (79) 62 (19) 58 (76)
IIþ 25 (9) 10 (12) 5 (7)
IIIþ 7 (3) 1 (1) 1 (1)
Resting LVOT gradient, mm Hg 27  29 21  22 20  23 0.08
Phenotypic subtypes 0.09
Asymmetric septal hypertrophy
without obstruction
76 (28) 22 (27) 18 (24)
Asymmetric septal hypertrophy
with obstruction
177 (66) 56 (68) 47 (62)
Apical variant 15 (6) 4 (5) 11 (15)
Post-stress LVOT gradient, mm Hg 63  48 65  46 55  47 0.4
Peak-stress MR 0.2
None 24 (9) 9 (11) 12 (16)
1þ 127 (47) 31 (38) 39 (51)
IIþ 85 (32) 30 (37) 22 (29)
IIIþ 29 (11) 12 (15) 2 (3)
IVþ 3 (1) 0 (0) 1 (1)
Abnormal chronotropic reserve index 114 (43) 19 (23) 16 (21) <0.001
Heart rate recovery, beats/min 30  15 32  10 33  11 0.13
Values are mean  SD or n (%).
Abbreviations as in Tables 1 and 2.
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32met the composite endpoint. The breakdown of
individual endpoints was as follows: 27 deaths (6%),
13 appropriate ICD discharges (3%), and 19 pa-
tients (4%) who developed CHF requiring hospital
stay during follow-up. There were no sudden death
resuscitations during follow-up. The breakdown of
deaths was as follows: 17 sudden deaths, 7 due to
progressive CHF, 1 due to ICD infection, and 2uncertain etiologies. In the same patient with mul-
tiple endpoints, time to ﬁrst event was utilized as a
censoring cutoff. In addition, 8 patients (2%) also
developed a stroke (all embolic) during follow-up.
In patients who experienced events during follow-
up, the resting and maximal LVOT gradients
were not sufﬁciently elevated to recommend surgery,
measuring 24  22 mm Hg and 34  32 mm Hg,
respectively.
Using the composite endpoint, the data on uni-
variate and stepwise multivariate Cox proportional
hazards survival analysis are shown in Tables 3 and 4,
respectively. Percent age-sex predicted METs ach-
ieved, HRR at 1 min in recovery, and AF inde-
pendently predicted composite events. During
follow-up, there were no signiﬁcant differences in
event rates within subgroups (16 [14%] in the
nonobstructive subgroup, 30 [11%] in the obstruc-
tive subgroup, and 6 [20%] in the apical hypertro-
phy subgroup; p ¼ 0.3). Kaplan-Meier curves
demonstrating the composite outcomes of the 3
phenotypic subgroups are shown in Figure 1. We
also performed survival analysis using “hard events”
(death and ICD discharge, excluding CHF admis-
sion). The ﬁndings were similar, with percent of
age-sex predicted METs achieved (HR: 0.81; 95%
CI: 0.71 to 0.94; p ¼ 0.001), HRR at 1 minute in
recovery (HR: 0.92; 95% CI: 0.85 to 0.98; p ¼
0.03) and AF (HR: 2.2; 95% CI: 1.06 to 4.59; p ¼
0.03) independently predicting hard events on
stepwise multivariate regression analysis.
The number of patients meeting the composite
endpoint was signiﬁcantly higher in the group that
achieved <7 METs (median) as compared to those
who achieved $7 METs (39 of 215 [18%] vs. 13 of
211 [6%]; p ¼ 0.001). Because exercise capacity is
highly dependent on age and sex, we further divided
patients into 3 subgroups on the basis of ratio of
achieved METs to age-sex predicted METs, as
follows: >100%, 85% to 100%, and <85%. Rele-
vant data in these 3 subgroups are shown in Table 5.
As expected, patients achieving <85% predicted
METs had a greater body surface area, greater beta-
blocker use, greater maximal LV thickness and left
atrial area. However, patients achieving <85% were
signiﬁcantly younger and less likely to be hyper-
tensive. Of note, 55% of patients who achieved
<85% of predicted METs reported no symptoms
(NYHA functional class I). The event rates of these
3 subgroups were signiﬁcantly different (1 of 76
[1%], 8 of 82 [10%], and 31 of 268 [12%],
respectively; p < 0.001). The Kaplan-Meier curves
of patients separated into these 3 subgroups are
shown in Figure 2. In patients who achieved
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33>100% of their age-sex predicted METs, the event
rate was extremely low.
The number of patients meeting the composite
endpoint was signiﬁcantly higher in the group with
abnormal versus normal HRR (8 of 25 [32%] vs. 31
of 401 [8%]; p < 0.001). The Kaplan-Meier curves
of patients separated on the basis of abnormal HRR
are shown in Figure 3. Similarly, the event rate
was signiﬁcantly higher in patients with AF versus
those without (15 of 52 [29%] vs. 37 of 374 [10%];
p < 0.03). The Kaplan-Meier curves of patients
separated on the basis of the presence of AF during
follow-up are shown in Figure 4.Figure 2. Outcomes by Predicted METs
Kaplan-Meier curves demonstrating long-term outcomes, by percent of predicted metabolic
equivalents (METs) achieved.
Figure 3. Outcomes by HRR
Kaplan-Meier curves demonstrating long-term outcomes, by normal or abnormal heart rate
recovery (HRR).DISCUSS ION
In the current study of HCM patients undergoing
stress echocardiography, we demonstrated that
functional capacity was an independent predictor
of outcomes. To avoid the confounding effect of
invasive therapies to relieve LVOT obstruction, we
excluded patients with intractable symptoms who
required such therapies (surgical myectomy with or
without mitral valve surgery or alcohol ablation)
because these patients have excellent outcomes
(5–12). We also excluded elderly patients with
hypertensive heart disease and concomitant
LVOT obstruction because they have pathophys-
iologic and genetic proﬁles different from those of
typical HCM patients (17–20). Patients with
impaired exercise capacity (achieved METS
< median) were 3 times as likely to have events
versus those with a preserved functional capacity.
In fact, if the patients achieved 100% of age-sex
predicted METs, the event rate was 1% during
follow-up, versus those achieving #85% of ex-
pected METs, who had an event rate of 12% during
follow-up. This is important because no patient
was deemed symptomatic enough to recommend
surgery or alcohol ablation. Also, in patients with
subsequent events, the resting and maximal LVOT
gradients remained low during follow-up, justifying
the recommendation to not perform invasive
therapies. More importantly, the current study
demonstrates that patients’ perceptions about their
symptoms can be misleading because all of the
patients deemed themselves asymptomatic or
minimally symptomatic (NYHA functional class
I–II) at the time of initial presentation. In these
instances, exercise testing can further aid in risk
stratiﬁcation for future events. This is similar to
what has been previously described in other pop-
ulations (13–15).Exercise intolerance is related to an inability to
increase stroke volume due to impaired LV con-
tractile reserve to overcome afterload in obstructed
patients and impaired ﬁlling in those who are not.
Previous studies have demonstrated safety and in-
cremental utility of performing exercise stress
echocardiography in HCM patients (25,34). In a
previous study, exercise echocardiography was
deemed safe, with a major event rate of 0.04% and a
minor event rate of 23% (25). In another study, the
incidence of arrhythmias during exercise echocar-
diography was 45%, without any major adverse
events at the time of testing (34). According
Figure 4. Outcomes by Atrial Fibrillation
Kaplan-Meier curves demonstrating long-term outcomes, by atrial ﬁbrillation in follow-up.
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34to recent guidelines, exercise echocardiography
is recognized as an important adjunct in the man-
agement of patients with HCM (3). Also, previous
reports have utilized stress echocardiography to
predict outcomes in HCM patients. In one study,
abnormal exercise capacity and LV function were
associated with worse outcomes (35). In another
study, severity of resting LVOT gradient and
percent of predicted peak myocardial oxygen con-
sumption during exercise were predictive of out-
comes (36). However, these were relatively small
studies with much shorter follow-up. For the cur-
rent study, to account for potential differences in
exercise capacity, on the basis of age and sex, we also
calculated a percentage of age-sex predicted METs
in every individual, rather than utilizing absolute
METs achieved or only age-based correction. We
utilized previously validated formulas that have been
demonstrated to have the most optimal performance
to predict age-based METs, separately in men and
women (28).
Also, abnormal HRR was predictive of long-term
outcomes, similar to previous reports (16). HRR
during the ﬁrst minute of recovery is reﬂective of
vagal reactivation, which tends to be blunted in
patients with CHF. Previous smaller reports have
indeed demonstrated that HCM patients with VT
have a reduction in parasympathetic activity (37).
This could potentially explain the association be-
tween sudden death (or ICD discharges) and
abnormal HRR. It appears that impaired exercise
capacity and abnormal HRR identify HCM pa-
tients who have a higher risk of death, malignant
arrhythmias, or progression to CHF, which in partcould be mediated by cardiac autonomic dysfunction
(38,39). Previous reports have demonstrated AF to
predict outcomes in HCM patients (5,40–43);
however, none evaluated a large cohort undergoing
exercise echocardiography, as in the current study.
In our study, previously reported HCM-related vari-
ables, including standard clinical risk factors, diastolic
function, LV thickness, resting/provocable LVOT
gradient, resting/post-stress MR, or abnormal BP
response to stress, were not predictive of long-term
outcomes (3). One potential reason for this is that
these patients represented a less sick cohort.
Study limitations. This was an observational expe-
rience from a single tertiary center, which could
have potential selection bias because we included
only patients who were able to undergo exercise
echocardiography. Tissue Doppler indices for the
assessment of diastolic function (i.e., E/e0) were not
uniformly available in the study population and
hence not reported. Because cardiopulmonary ex-
ercise data were not uniformly available in patients
seen during the early part of the study, variables
such as VO2 max are not reported. Right ventricular
systolic pressure at peak stress was not uniformly
available in all patients and hence is not reported.
We utilized a composite endpoint that weighted the
development of CHF admission similar to sudden
death or its surrogates.CONCLUS IONS
We demonstrate that in asymptomatic or minimally
symptomatic HCM patients who did not undergo
invasive therapies for relief of LVOT obstruction,
reduced exercise capacity and abnormal HRR on
exercise echocardiography independently predict
composite endpoints, in addition to the presence
of AF. We also demonstrate that patients who
achieved $100% of age-sex predicted METs had
excellent long-term outcomes, with a very low
event rate, regardless of the degree of LVOT
obstruction or other HCM-related risk factors. In
asymptomatic or minimally symptomatic HCM
patients, exercise stress testing is a safe and useful
tool that enables excellent risk stratiﬁcation of
individuals.Reprint requests and correspondence: Dr. Milind Y.
Desai, Heart and Vascular Institute, Cleveland Clinic,
9500 Euclid Avenue, Desk J1-5, Cleveland,
Ohio 44195. E-mail: desaim2@ccf.org.
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